Letter: risk of severe COVID-19 outcomes associated with inflammatory bowel disease medications-reassuring insights from the United Kingdom PREPARE-IBD multicentre cohort study

Aliment Pharmacol Ther. 2021 Jun;53(11):1236-1240. doi: 10.1111/apt.16349.

Abstract

LINKED CONTENT

This article is linked to Taxonera et al paper. To view this article, visit https://doi.org/10.1111/apt.15804

Publication types

  • Letter
  • Comment

MeSH terms

  • COVID-19*
  • Cohort Studies
  • Humans
  • Inflammatory Bowel Diseases* / complications
  • Inflammatory Bowel Diseases* / drug therapy
  • Inflammatory Bowel Diseases* / epidemiology
  • SARS-CoV-2
  • United Kingdom / epidemiology